Redeye thinks the Q1 report was soft and that the outlook remains uncertain. While Catella is trading at a substantial discount to Redeye's intrinsic value, the stock lacks short-term catalysts. Looking into 2024, Redeye expects a rebound in group profitability and harvesting of Principal Investments will fuel the share price. Redeye lowers its estimates and fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/